{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"-1.0"},{"groupId":"OG001","spread":"1.2","value":"1.7"}]}],"title":"Physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1","value":"-1.4"},{"groupId":"OG001","spread":"1.6","value":"2.9"}]}],"title":"Role"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"4.7"},{"groupId":"OG001","spread":"1.3","value":"4.0"}]}],"title":"Emotional"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"-4.0"},{"groupId":"OG001","spread":"1.3","value":"-4.0"}]}],"title":"Cognitive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"-0.1"},{"groupId":"OG001","spread":"1.4","value":"3.3"}]}],"title":"Social"}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains(physical,role,cognitive,emotional, and social),global health status, and symptom scales of fatigue, pain, nausea and vomiting,dyspnea,loss of appetite,insomnia,constipation and diarrhea, and financial difficulties.Functional scale options are defined on a 7-point scale ranging from 1, \"Very poor\" to 7, \"Excellent\". A linear transformation is applied to standardize the raw scores to range between 0 and 100 with higher score indicating better functioning. For functional domains and global health status, higher scores represent a better level of functioning. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\\*Visit and Baseline.","dispersionType":"Standard Error","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up to 32 Months)","title":"Change From Baseline to End of Study in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Functional Scale Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}